Alfredo Quijano Rubio is a scientist and entrepreneur specializing in computational protein design. He is the co-founder and Chief Scientific Officer (CSO) of Monod Bio, a company pioneering the design of novel diagnostics and research reagents using AI-powered computational protein design. He obtained a Ph.D. in Bioengineering at the University of Washington under the mentorship of Professor David Baker, Nobel Prize in Chemistry in 2024. His research on designing conditionally-active proteins for immunotherapy and biosensors resulted in high-impact scientific publications, patents, and the creation of two companies: Neoleukin Therapeutics and Monod Bio. Alfredo has been recognized by Business Insider and by the Puget Sound Business Journal as one of the young leaders revolutionizing the healthtech sector.